Key result
Elevated HbA1c was an independent risk factor for posthospital mortality in AMI survivors with impaired glucose tolerance and newly detected diabetes.
Why the study?
Does elevated HbA1c increase posthospital mortality in patients with AMI treated invasively and newly detected glucose abnormalities?
Cohort (n=2,146)
No
Does elevated HbA1c increase posthospital mortality in patients with AMI treated invasively and newly detected glucose abnormalities?
Elevated HbA1c is a strong independent predictor of posthospital mortality in patients with AMI and newly diagnosed glucose abnormalities.
Answers are grounded in this paper and cite their sources.
Supports HbA1c monitoring for risk stratification in AMI survivors with new glucose abnormalities; leaves open whether intervention improves survival.
BACKGROUND: Glucose abnormalities are frequent comorbidities influencing prognosis in patients with cardiovascular diseases. The objective of this study was to evaluate prognostic role of HbA1c in patients with acute myocardial infarction (AMI) treated invasively, who had newly detected glucose abnormalities. DESIGN: Single-centre registry encompassed 2146 survivors of AMI. In all patients without diabetes mellitus (DM), oral glucose tolerance test was performed before hospital discharge and interpreted according to the guidelines. METHODS: From the study population, two major groups with defined new glucose abnormalities and estimated HbA1c were selected: 457 patients with impaired glucose tolerance (IGT) and 306 patients with newly detected DM (newDM). In each of these groups, the median value of HbA1c was calculated and established as the cut-off point for further analysis. The median HbA1c for IGT group was 5.9% and for newDM was 7.0%. RESULTS: Patients with IGT and HbA1c ≤ 5.9% had significantly lower posthospital mortality (4.5%) than those with HbA1c >5.9% (25.0%; p<0.001). Similarly, patients with newDM and HbA1c ≤7.0% had lower mortality (6.4%) than those with HbA1c >7.0% (14.3%; p<0.05). Multivariate regression analysis revealed that increase of HbA1c was one of the strongest independent risk factors of death among IGT patients (HR 2.9, 95% CI 2.7-3.1; p < 0.001) and newDM (HR 1.53, 95% CI 1.39-1.66; p<0.05). CONCLUSIONS: Increase of HbA1c in patients with newly detected glucose abnormalities was associated with significantly reduced survival after AMI treated invasively. Moreover, increase of HbA1c in patients with IGT and newDM was one of the strongest independent risk factors of death in these populations.
No takes yet. Share an insight, caveat, or question.
Kowalczyk et al. (2014) conducted a cohort in Acute myocardial infarction with newly detected glucose abnormalities (n=2,146). Elevated HbA1c (>5.9% in impaired glucose tolerance) vs. HbA1c ≤5.9% was evaluated on posthospital mortality in patients with impaired glucose tolerance (HR 2.9, 95% CI 2.7-3.1, p=<0.001). Elevated HbA1c was an independent risk factor for posthospital mortality in AMI survivors with impaired glucose tolerance and newly detected diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: